CD5、BCL2和MYC过表达对弥漫大B细胞淋巴瘤预后的探讨.pdfVIP

目 录 摘要 ······························································ ···························· 1 Abstract ······················································ ································ 3 前言 ······························································ ···························· 6 材料与方法 ······························································ ··················· 7 结果 ····························································· ···························· 9 讨论 ····························································· ··························· 16 结论 ······························································ ··························· 19 附图 ······························································ ··························· 20 参考文献 ······························································ ····················· 23 综述： ······························································ ························ 27 攻读学位期间发表文章情况 ···························································· 49 致谢 ······························································ ··························· 50 个人简历 ······························································ ····················· 51 CD5、BCL2和 MYC过表达对弥漫大 B细胞淋巴瘤预后的探讨 摘要 背景 弥漫大 B 细胞淋巴瘤（Diffuse large B cell lymphoma ，DLBCL ）是成人非霍奇金 淋巴瘤中最常见的一种侵袭性淋巴瘤，在临床表现、形态学、生物学行为上均存在异 质性，应用 RCHOP 标准方案治疗仍有 30%-40%患者出现复发/难治。WHO 建议对 DLBCL 患者行细胞起源分类以及 FISH 基因检测。NCCN 指南指出双打击/三打击淋 巴瘤患者预后差，MYC/BCL2 双表达也是 DLBCL 的不良预后因素。多数研究发现原 发 CD5 阳性DLBCL 患者预后差，因此有必要充分研究DLBCL 相关的生物标志物为 患者进行危险分层、预后分析、指导治疗。 目的 探讨 CD5、BC